ABIVAX Société Anonyme (ABVX)

CIK 0001956827 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
—
Auditor Information
—
Statements
Consolidated Statements of Financial Position
—
Consolidated Statements of Financial Position (P)
—
Consolidated Statements of Income (loss)
—
Consolidated Statements of Comprehensive Income (loss)
—
Consolidated Statements of Changes In Shareholders Equity
—
Consolidated Statements of Cash Flows
—
Notes
Accounting Principles
—
Basis of Preparation
—
Cash and Cash Equivalents
—
Cybersecurity Risk Management and Strategy Disclosure
—
Employees
—
Financial Assets and Liabilities
—
Financial Gain (loss)
—
Financial Liabilities
—
Goodwill and Impairment Test
—
Income (loss) Per Share
—
Income Tax
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Management and Assessment of Financial Risks
—
Off-balance Sheet Commitments Given
—
Off-balance Sheet Commitments Received and Contingent Assets
—
Operating Expenses
—
Operating Income
—
Other Financial Assets
—
Other Operating Income
—
Other Receivables and Other Assets
—
Payables and Other Current Liabilities
—
Property, Plant and Equipment
—
Related Parties
—
Retirement Benefit Obligations
—
Segment Information
—
Share-based Payments
—
Shareholders Equity
—
Significant Events For The Years Ended December 31, 2021, 2022 and 2023 and Subsequent Events
—
Significant Events For The Years Ended December 31, 2022, 2023 and 2024 and Subsequent Events
—
Significant Events For The Years Ended December 31, 2023, 2024 and 2025 and Subsequent Events
—
The Group
—